BR112022023462A2 - 2-amino-3-ciano tiofenos anulados e derivados para o tratamento de câncer - Google Patents
2-amino-3-ciano tiofenos anulados e derivados para o tratamento de câncerInfo
- Publication number
- BR112022023462A2 BR112022023462A2 BR112022023462A BR112022023462A BR112022023462A2 BR 112022023462 A2 BR112022023462 A2 BR 112022023462A2 BR 112022023462 A BR112022023462 A BR 112022023462A BR 112022023462 A BR112022023462 A BR 112022023462A BR 112022023462 A2 BR112022023462 A2 BR 112022023462A2
- Authority
- BR
- Brazil
- Prior art keywords
- treatment
- thiophenes
- cyan
- deleted
- cancer
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
Abstract
A presente invenção refere-se a compostos de fórmula (I) em que R1a, R1b, R2a, R2b, Z, R3 a R5, A, p, U, V, W, L e E têm os significados fornecidos nas reivindicações e especificações, seu uso como inibidores de proteínas mutantes da família Ras, composições farmacêuticas e preparações contendo tais compostos e seu uso como medicamentos/usos médicos, especialmente como agentes para tratamento e/ou prevenção de doenças oncológicas.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063033505P | 2020-06-02 | 2020-06-02 | |
EP20212067 | 2020-12-05 | ||
PCT/EP2021/064612 WO2021245051A1 (en) | 2020-06-02 | 2021-06-01 | Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112022023462A2 true BR112022023462A2 (pt) | 2022-12-20 |
Family
ID=76269742
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112022023462A BR112022023462A2 (pt) | 2020-06-02 | 2021-06-01 | 2-amino-3-ciano tiofenos anulados e derivados para o tratamento de câncer |
Country Status (18)
Country | Link |
---|---|
US (2) | US11945812B2 (pt) |
EP (2) | EP4157837A1 (pt) |
JP (2) | JP2023528623A (pt) |
KR (1) | KR20230019462A (pt) |
CN (2) | CN116034106A (pt) |
AU (1) | AU2021285032A1 (pt) |
BR (1) | BR112022023462A2 (pt) |
CA (1) | CA3183656A1 (pt) |
CL (1) | CL2022003289A1 (pt) |
CO (1) | CO2022017049A2 (pt) |
CR (1) | CR20220614A (pt) |
DO (1) | DOP2022000266A (pt) |
EC (1) | ECSP22089077A (pt) |
IL (1) | IL298633A (pt) |
MX (1) | MX2022015260A (pt) |
PE (1) | PE20240493A1 (pt) |
TW (1) | TW202210474A (pt) |
WO (2) | WO2021245051A1 (pt) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019217307A1 (en) | 2018-05-07 | 2019-11-14 | Mirati Therapeutics, Inc. | Kras g12c inhibitors |
EP3908283A4 (en) | 2019-01-10 | 2022-10-12 | Mirati Therapeutics, Inc. | KRAS G12C INHIBITORS |
US11453683B1 (en) | 2019-08-29 | 2022-09-27 | Mirati Therapeutics, Inc. | KRas G12D inhibitors |
JP2022548791A (ja) | 2019-09-24 | 2022-11-21 | ミラティ セラピューティクス, インコーポレイテッド | 組み合わせ療法 |
MX2022007515A (es) | 2019-12-20 | 2022-09-19 | Mirati Therapeutics Inc | Inhibidores de sos1. |
US11945812B2 (en) | 2020-06-02 | 2024-04-02 | Boehringer Ingelheim International Gmbh | Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer |
WO2022133345A1 (en) | 2020-12-18 | 2022-06-23 | Erasca, Inc. | Tricyclic pyridones and pyrimidones |
BR112023022819A2 (pt) | 2021-05-05 | 2024-01-16 | Revolution Medicines Inc | Compostos, composição farmacêutica, conjugados e métodos para tratar câncer em um sujeito, para tratar um distúrbio e para inibir uma proteína ras em uma célula |
CN117616031A (zh) | 2021-05-05 | 2024-02-27 | 锐新医药公司 | 用于治疗癌症的ras抑制剂 |
WO2023099592A1 (en) * | 2021-12-01 | 2023-06-08 | Boehringer Ingelheim International Gmbh | Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer |
TW202340209A (zh) | 2021-12-01 | 2023-10-16 | 德商百靈佳殷格翰國際股份有限公司 | 用於治療癌症之環狀2-胺基-3-氰基噻吩及衍生物 |
TW202337432A (zh) * | 2021-12-01 | 2023-10-01 | 德商百靈佳殷格翰國際股份有限公司 | 用於治療癌症之環狀2-胺基-3-氰基噻吩及衍生物 |
WO2023099620A1 (en) * | 2021-12-01 | 2023-06-08 | Boehringer Ingelheim International Gmbh | Kras degrading compounds comprising annulated 2-amino-3-cyano thiophenes |
WO2023117681A1 (en) * | 2021-12-22 | 2023-06-29 | Boehringer Ingelheim International Gmbh | Heteroaromatic compounds for the treatment of cancer |
TW202333800A (zh) | 2021-12-28 | 2023-09-01 | 英商阿斯特捷利康英國股份有限公司 | 抗體-藥物結合物及rasg12c抑制劑之組合 |
WO2023154766A1 (en) | 2022-02-09 | 2023-08-17 | Quanta Therapeutics, Inc. | Kras modulators and uses thereof |
WO2023172940A1 (en) | 2022-03-08 | 2023-09-14 | Revolution Medicines, Inc. | Methods for treating immune refractory lung cancer |
WO2023240263A1 (en) | 2022-06-10 | 2023-12-14 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
WO2023244599A1 (en) * | 2022-06-15 | 2023-12-21 | Mirati Therapeutics, Inc. | Pan-kras inhibitors |
Family Cites Families (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK2376116T3 (en) | 2008-12-12 | 2016-02-29 | Boehringer Ingelheim Int | The anti-IGF antibodies. |
AR090151A1 (es) | 2012-03-07 | 2014-10-22 | Lilly Co Eli | Compuestos inhibidores de raf |
CU24335B1 (es) | 2012-03-14 | 2018-04-03 | Lupin Ltd | Piridopirimidinas sustituidas como inhibidores de la quinasa mek y útiles para el tratamiento del cáncer |
US9242969B2 (en) | 2013-03-14 | 2016-01-26 | Novartis Ag | Biaryl amide compounds as kinase inhibitors |
BR112016008016B8 (pt) | 2013-10-10 | 2023-09-26 | Araxes Pharma Llc | Compostos inibidores de kras g12c, composição farmacêutica compreendendo ditos compostos, métodos para regular a atividade e para preparar uma proteína mutante kras, hras ou nras g12c, método para inibir a proliferação de uma população de células e usos terapêuticos dos ditos compostos |
WO2015155332A1 (en) | 2014-04-11 | 2015-10-15 | Boehringer Ingelheim International Gmbh | Spiro[3h-indole-3,2'-pyrrolidin]-2(1h)-one derivatives and their use as mdm2-p53 inhibitors |
EP3164401B1 (en) | 2014-07-03 | 2018-12-26 | Boehringer Ingelheim International GmbH | New spiro[3h-indole-3,2´-pyrrolidin]-2(1h)-one compounds and derivatives as mdm2-p53 inhibitors |
MX2017002260A (es) | 2014-08-21 | 2017-05-03 | Boehringer Ingelheim Int | Nuevos compuestos de espiro[3h-indol-3,2´-pirrolidin]-2(1h)-ona y derivados como inhibidores de mdm2-p53. |
MX2018004207A (es) | 2015-10-09 | 2018-07-06 | Boehringer Ingelheim Int | Nuevos compuestos de espiro[3h-indol-3,2â´-pirrolidin]-2(1h)-ona y derivados como inhibidores de mdm2-p53. |
ES2863873T3 (es) | 2016-05-18 | 2021-10-11 | Mirati Therapeutics Inc | Inhibidores de KRAS G12C |
CN110603254B (zh) | 2016-11-30 | 2024-04-12 | 班塔姆制药有限责任公司 | 被取代的吡唑化合物以及使用其治疗过度增生性疾病的方法 |
KR20230150408A (ko) * | 2016-12-22 | 2023-10-30 | 암젠 인크 | 폐암, 췌장암 또는 대장암을 치료하기 위한 kras g12c 억제제로서의 벤즈이소티아졸, 이소티아졸로[3,4-b]피리딘, 퀴나졸린, 프탈라진, 피리도[2,3-d]피리다진 및 피리도[2,3-d]피리미딘 유도체 |
EP3558979B1 (en) | 2016-12-22 | 2021-02-17 | Boehringer Ingelheim International GmbH | Novel benzylamino substituted quinazolines and derivatives as sos1 inhibitors |
EP3573964A1 (en) | 2017-01-26 | 2019-12-04 | Araxes Pharma LLC | Benzothiophene and benzothiazole compounds and methods of use thereof |
US20220235013A1 (en) | 2017-03-21 | 2022-07-28 | Bayer Pharma Aktiengesellschaft | 2-methyl-quinazolines |
JOP20190272A1 (ar) | 2017-05-22 | 2019-11-21 | Amgen Inc | مثبطات kras g12c وطرق لاستخدامها |
US10689377B2 (en) | 2017-11-15 | 2020-06-23 | Mirati Therapeutics, Inc. | KRas G12C inhibitors |
AR114164A1 (es) | 2017-12-21 | 2020-07-29 | Boehringer Ingelheim Int | Piridopirimidinonas sustituidas con bencilamino y derivados como inhibidores de sos1 |
CA3097231A1 (en) | 2018-04-18 | 2019-10-24 | Bayer Pharma Aktiengesellschaft | 2-methyl-aza-quinazolines |
CN112584833A (zh) * | 2018-08-01 | 2021-03-30 | 亚瑞克西斯制药公司 | 杂环螺化合物及其用于治疗癌症的使用方法 |
JP2020090482A (ja) | 2018-11-16 | 2020-06-11 | アムジエン・インコーポレーテツド | Kras g12c阻害剤化合物の重要な中間体の改良合成法 |
WO2020177629A1 (zh) | 2019-03-01 | 2020-09-10 | 劲方医药科技(上海)有限公司 | 螺环取代的嘧啶并环类化合物,其制法与医药上的用途 |
CA3130083A1 (en) | 2019-03-01 | 2020-09-10 | Revolution Medicines, Inc. | Bicyclic heterocyclyl compounds and uses thereof |
JP2022522777A (ja) | 2019-03-01 | 2022-04-20 | レボリューション メディシンズ インコーポレイテッド | 二環式ヘテロアリール化合物及びその使用 |
CN114096544A (zh) | 2019-05-20 | 2022-02-25 | 加州理工学院 | Kras g12c抑制剂及其用途 |
MD3886991T2 (ro) | 2019-12-11 | 2023-03-31 | Lilly Co Eli | Inhibitori KRAS G12C |
WO2021120890A1 (en) | 2019-12-20 | 2021-06-24 | Novartis Ag | Pyrazolyl derivatives useful as anti-cancer agents |
CN113087700B (zh) | 2020-01-08 | 2023-03-14 | 苏州亚盛药业有限公司 | 螺环四氢喹唑啉 |
WO2021150613A1 (en) | 2020-01-20 | 2021-07-29 | Incyte Corporation | Spiro compounds as inhibitors of kras |
CN113683616A (zh) | 2020-05-18 | 2021-11-23 | 广州百霆医药科技有限公司 | Kras g12c突变蛋白抑制剂 |
US11945812B2 (en) | 2020-06-02 | 2024-04-02 | Boehringer Ingelheim International Gmbh | Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer |
TW202337432A (zh) | 2021-12-01 | 2023-10-01 | 德商百靈佳殷格翰國際股份有限公司 | 用於治療癌症之環狀2-胺基-3-氰基噻吩及衍生物 |
WO2023099592A1 (en) | 2021-12-01 | 2023-06-08 | Boehringer Ingelheim International Gmbh | Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer |
US20230227470A1 (en) | 2021-12-01 | 2023-07-20 | Boehringer Ingelheim International Gmbh | Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer |
WO2023099620A1 (en) | 2021-12-01 | 2023-06-08 | Boehringer Ingelheim International Gmbh | Kras degrading compounds comprising annulated 2-amino-3-cyano thiophenes |
TW202340208A (zh) | 2021-12-01 | 2023-10-16 | 德商百靈佳殷格翰國際股份有限公司 | 用於治療癌症之環狀2-胺基-3-氰基噻吩及衍生物 |
TW202340209A (zh) | 2021-12-01 | 2023-10-16 | 德商百靈佳殷格翰國際股份有限公司 | 用於治療癌症之環狀2-胺基-3-氰基噻吩及衍生物 |
-
2021
- 2021-06-01 US US17/335,620 patent/US11945812B2/en active Active
- 2021-06-01 JP JP2022574317A patent/JP2023528623A/ja active Pending
- 2021-06-01 BR BR112022023462A patent/BR112022023462A2/pt unknown
- 2021-06-01 US US18/000,442 patent/US20230212164A1/en active Pending
- 2021-06-01 CR CR20220614A patent/CR20220614A/es unknown
- 2021-06-01 EP EP21729877.7A patent/EP4157837A1/en active Pending
- 2021-06-01 PE PE2022002820A patent/PE20240493A1/es unknown
- 2021-06-01 KR KR1020227046273A patent/KR20230019462A/ko unknown
- 2021-06-01 TW TW110119842A patent/TW202210474A/zh unknown
- 2021-06-01 AU AU2021285032A patent/AU2021285032A1/en active Pending
- 2021-06-01 CN CN202180039453.3A patent/CN116034106A/zh active Pending
- 2021-06-01 WO PCT/EP2021/064612 patent/WO2021245051A1/en active Application Filing
- 2021-06-01 JP JP2022574134A patent/JP2023527891A/ja active Pending
- 2021-06-01 IL IL298633A patent/IL298633A/en unknown
- 2021-06-01 CN CN202180059643.1A patent/CN116234806A/zh active Pending
- 2021-06-01 WO PCT/EP2021/064616 patent/WO2021245055A1/en unknown
- 2021-06-01 EP EP21729875.1A patent/EP4157836A1/en active Pending
- 2021-06-01 MX MX2022015260A patent/MX2022015260A/es unknown
- 2021-06-01 CA CA3183656A patent/CA3183656A1/en active Pending
-
2022
- 2022-11-21 EC ECSENADI202289077A patent/ECSP22089077A/es unknown
- 2022-11-23 CL CL2022003289A patent/CL2022003289A1/es unknown
- 2022-11-25 DO DO2022000266A patent/DOP2022000266A/es unknown
- 2022-11-29 CO CONC2022/0017049A patent/CO2022017049A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
CN116234806A (zh) | 2023-06-06 |
IL298633A (en) | 2023-01-01 |
DOP2022000266A (es) | 2023-01-15 |
JP2023528623A (ja) | 2023-07-05 |
CR20220614A (es) | 2023-05-08 |
MX2022015260A (es) | 2023-01-11 |
KR20230019462A (ko) | 2023-02-08 |
WO2021245051A1 (en) | 2021-12-09 |
US11945812B2 (en) | 2024-04-02 |
TW202210474A (zh) | 2022-03-16 |
PE20240493A1 (es) | 2024-03-15 |
US20210380574A1 (en) | 2021-12-09 |
CL2022003289A1 (es) | 2023-04-14 |
CO2022017049A2 (es) | 2023-02-06 |
EP4157837A1 (en) | 2023-04-05 |
ECSP22089077A (es) | 2022-12-30 |
JP2023527891A (ja) | 2023-06-30 |
CN116034106A (zh) | 2023-04-28 |
AU2021285032A1 (en) | 2022-12-08 |
CA3183656A1 (en) | 2021-12-09 |
EP4157836A1 (en) | 2023-04-05 |
WO2021245055A1 (en) | 2021-12-09 |
US20230212164A1 (en) | 2023-07-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112022023462A2 (pt) | 2-amino-3-ciano tiofenos anulados e derivados para o tratamento de câncer | |
BR112022003184A2 (pt) | Inibidores de pirazolo[3,4-b]pirazina shp2 fosfatase | |
BRPI0515446A (pt) | amidas bicìclicas como inibidores de cinases | |
BR112021022796A2 (pt) | Inibidores de inflamassoma de nlrp3 | |
BR112022021514A2 (pt) | [1,3]diazino[5,4-d]pirimidinas como inibidores de her2 | |
BR112014019052A8 (pt) | Inibidores seletivos de cdk8/cdk19 e seu uso em métodos antimetastáticos e quimiopreventivos para câncer | |
BR112015025052A2 (pt) | derivados de n-fenil-carboxamida e o seu uso como medicamentos para o tratamento da hepatite b | |
BRPI0918602B8 (pt) | inibidores da atividade de ssao, seu uso, e formulação farmacêutica | |
BR112015024078A2 (pt) | derivados de benzimidazolona como inibidores de bromodomínio | |
BR112015024671A2 (pt) | derivados de ureia úteis como inibidores de quinase | |
BR112022000251A2 (pt) | Derivados macrocíclicos de espirociclo como inibidores de mcl-1 | |
BR112015026238A8 (pt) | composto dihidropirazino-pirazina, composição farmacêutica que o compreende, uso do composto, métodos para inibir ou medir a fosforilação e para inibir a atividade da proteína quinase, bem como kit | |
BR112023000212A2 (pt) | Éter macrocíclico contendo derivados de indol como inibidores de mcl-1 | |
BR112015019412A8 (pt) | inibidores de bace1, seus usos, e composição farmacêutica | |
BR112015019811A2 (pt) | 2,3-benzodiazepinas bicíclicas e 2,3-benzodiazepinas espirocíclicas substituídas | |
BR112022008000A2 (pt) | Derivado de pirazol-heteroarila, método de preparação para o mesmo e uso médico do mesmo | |
CR20220068A (es) | Derivados de 2-morfolinopiridina sustituidos como inhibidores de la cinasa atr | |
BR112021025732A2 (pt) | Inibidores macrocíclicos de mcl-1 | |
BR112022001567A2 (pt) | Derivados de isoquinolina e seu uso para o tratamento de infecções parasitárias. | |
BR112022019057A2 (pt) | Aminotiazóis substituídos como inibidores de dgkzeta para ativação imune | |
BR112023022496A2 (pt) | Composto heterocíclico contendo nitrogênio, método de preparação do mesmo, e aplicação do mesmo em medicamentos | |
BR112020020708A8 (pt) | Derivados da ureia cíclica fundidã como antagonista crhr2 | |
BR112021017957A2 (pt) | Derivado tienoeterocíclico, método de preparação do mesmo e uso médico do mesmo | |
BR112018072298A2 (pt) | tratamento de infecções pelo vírus da zika usando inibidores da alfa-glicosidase | |
BR112022013488A2 (pt) | Pirazolo-pirimidinas substituídas e seu uso |